Biotech

ImmunoPrecise Announces R&D Positive Results Using the OmniAb Platform

Biotech

ImmunoPrecise Antibodies announced it is now an approved contract research organization for the development of human monoclonal antibodies with the OmniAb platform.

ImmunoPrecise Antibodies (TSXV:IPA; OTCPINK:IPATF) announced it is now an approved contract research organization for the development of human monoclonal antibodies with the OmniAb platform.
As quoted in the press release:

The OmniAb platform consists of the OmniRat, OmniMouse and OmniFlic transgenic rodents.  These rodents are bred to produce highly diversified antibody repertoires for the discovery of fully human antibodies with potentially superior therapeutic efficacy and reduced immunogenicity. The OmniAb platform is owned by Ligand Pharmaceuticals.
ImmunoPrecise Antibodies has now completed two research and development projects, which allowed the Company to test and optimize its unique and proprietary methodologies, including the Rapid Prime immunization protocol.

Click here to read the full press release.

Source: www.newswire.ca

MARKETS

Markets
TSX20700.50+100.90
TSXV621.14-1.48
DOW33949.41+205.57
S&P 5004060.43+44.21
NASD11512.41+199.06
ASX7468.30-22.10

COMMODITIES

Commodities
Gold1930.32-0.01
Silver23.73-0.17
Copper4.270.00
Palladium1713.170.00
Platinum1087.260.00
Oil82.26+1.25
Heating Oil3.32+0.03
Natural Gas2.92-0.02

DOWNLOAD FREE REPORTS

×